trial · primary record
Sarilumab
Any Advanced Solid Tumors
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 41 |
| Primary completion | 2029-12 |
| Primary endpoint | Safety as assessed by Absence of any grade ≥2 Immune Related Adverse Event (irAE) |
| Registry ID | NCT07836101 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:27.255Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07836101
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Sarilumab · compound